Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.

An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.

Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.

SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.